Though pancreatitis is common among other diabetes medications, such as GLP-1 mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors, it is not recognized by the FDA as an adverse effect of SGLT-2 inhibitor use. This evidence concerns the gene DPP4 and pancreatitis.